price down icon2.43%   -0.35
after-market  After Hours:  14.03  -0.02   -0.14%
Novavax, Inc. stock is currently priced at $14.05, with a 24-hour trading volume of 9.36M. It has seen a -2.43% decreased in the last 24 hours and a +7.99% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $14.26 pivot point. If it approaches the $13.64 support level, significant changes may occur.
Previous Close:
24h Volume:
Market Cap:
Net Income/Loss:
P/E Ratio:
Net Cash Flow:
1W Performance:
1M Performance:
6M Performance:
1Y Performance:
1D Range:
52W Range:

Novavax, Inc. Stock (NVAX) Company Profile

Novavax, Inc.
20 Firstfield Road, Gaithersburg, MD
Next Earnings Date
Latest SEC Filings
NVAX's Discussions on Twitter

Novavax, Inc. Stock (NVAX) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-09-23 Upgrade B. Riley Securities Neutral → Buy
Apr-20-23 Downgrade TD Cowen Outperform → Market Perform
Mar-01-23 Downgrade B. Riley Securities Buy → Neutral
Jan-09-23 Reiterated B. Riley Securities Buy
Dec-30-22 Reiterated H.C. Wainwright Buy
Dec-02-22 Initiated Jefferies Hold
Sep-22-22 Downgrade JP Morgan Neutral → Underweight
May-20-22 Initiated BofA Securities Underperform
Feb-23-22 Reiterated B. Riley Securities Buy
Feb-22-22 Resumed Jefferies Buy
Jan-21-22 Initiated Cowen Outperform
May-12-21 Downgrade JP Morgan Overweight → Neutral
Dec-14-20 Initiated Jefferies Buy
Aug-06-20 Reiterated H.C. Wainwright Buy
Aug-05-20 Upgrade JP Morgan Neutral → Overweight
Aug-05-20 Downgrade Ladenburg Thalmann Neutral → Sell
Jul-16-20 Reiterated H.C. Wainwright Buy
Jul-08-20 Downgrade Ladenburg Thalmann Buy → Neutral
Jun-29-20 Reiterated B. Riley FBR Buy
Jun-29-20 Reiterated H.C. Wainwright Buy
Jun-05-20 Upgrade JP Morgan Underweight → Neutral
May-28-20 Reiterated B. Riley FBR Buy
May-12-20 Reiterated H.C. Wainwright Buy
Apr-30-20 Reiterated H.C. Wainwright Buy
Nov-27-19 Resumed B. Riley FBR Buy
Aug-14-19 Reiterated H.C. Wainwright Buy
Feb-28-19 Downgrade Piper Jaffray Overweight → Underweight
Dec-18-18 Initiated Ladenburg Thalmann Buy
Dec-11-18 Initiated Oppenheimer Outperform
Nov-26-18 Upgrade Piper Jaffray Neutral → Overweight
Sep-21-18 Upgrade JP Morgan Underweight → Overweight
Mar-29-18 Upgrade Seaport Global Securities Neutral → Buy
View All

Novavax, Inc. Stock (NVAX) Financials Data

Novavax, Inc. (NVAX) Revenue 2024

NVAX reported a revenue (TTM) of $693.46 million for the quarter ending December 31, 2023, a -59.37% decline year-over-year.

Novavax, Inc. (NVAX) Net Income 2024

NVAX net income (TTM) was -$545.06 million for the quarter ending December 31, 2023, a +17.16% increase year-over-year.

Novavax, Inc. (NVAX) Cash Flow 2024

NVAX recorded a free cash flow (TTM) of -$772.77 million for the quarter ending December 31, 2023, a -51.85% decrease year-over-year.

Novavax, Inc. (NVAX) Earnings per Share 2024

NVAX earnings per share (TTM) was -$5.56 for the quarter ending December 31, 2023, a +33.81% growth year-over-year.
Novavax, Inc., together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, enhance its specificity to provide protection against related microorganisms, as well as allows immunization with much lower doses of antigen. The company develops respiratory syncytial (RSV) virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III clinical trial; older adults in Phase II clinical trial; and children six months to five years of age in Phase I clinical trial. Novavax, Inc. also develops NanoFlu vaccine, which is in Phase I/II clinical trial for treating seasonal influenza in older adults; and Ebola virus glycoprotein vaccine that is in Phase I clinical trial. Its preclinical programs include Zika virus; combination respiratory vaccine candidate to protect against RSV and seasonal influenza, as well as other infectious disease vaccine candidates. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.
price up icon 1.81%
price down icon 1.57%
price down icon 1.97%
price down icon 1.93%
price down icon 3.95%
price down icon 2.25%
Cap:     |  Volume (24h):